Zentalis Pharmaceuticals
Clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $250m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (169514 %) | - | - | - | - | - | (308 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (150479 %) | - | - | - | - | - | (246 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 135150 % | - | - | - | - | - | 249 % |
Source: Company filings or news article
Related Content
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics for cancer treatment. The company operates in the oncology sector, targeting fundamental biological pathways of cancers to create clinically differentiated therapies. Zentalis primarily serves patients suffering from various forms of cancer, including advanced non-Hodgkin lymphoma and acute myeloid leukemia. The company's business model revolves around its Integrated Discovery Engine, which efficiently identifies and develops novel oncology therapies by focusing on clinically validated and commercially proven targets. Zentalis generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. The company aims to improve patient outcomes and make a lasting impact on the field of oncology.
Keywords: oncology, biopharmaceutical, cancer treatment, small molecule therapeutics, clinical-stage, drug discovery, Integrated Discovery Engine, non-Hodgkin lymphoma, acute myeloid leukemia, patient outcomes.